CompuGroup stock holds recent gains as digital health demand supports outlook

CompuGroup Medical SE (ISIN DE000A288904) stock is quoted at EUR 27.95 as of September 7, 2026, with a 24-hour move of minus 0.09 percent according to data from wallstreet-online.

Stock trades below 52-week high

According to the real-time quote overview from wallstreet-online, CompuGroup Medical shares are down 2.71 percent over the past month and stand 9.42 percent below their 52-week high while remaining 19.33 percent above the 52-week low as of September 7, 2026.

The same overview shows a positive year-to-date performance of 10.27 percent for CompuGroup Medical, indicating that despite the recent consolidation the stock has delivered a solid gain for investors so far in 2026.

Recent fundamentals and growth momentum

While no new earnings release has been published in the last few days, the current market narrative around CompuGroup Medical stock is still driven by the most recently reported figures for the latest completed financial period, which investors use to gauge the company’s ability to benefit from ongoing digitalization in healthcare.

Financial portals summarizing the latest available full-year figures for CompuGroup Medical indicate that the company reported revenue in the most recent fiscal year within the 9-month freshness window up to September 7, 2026, and that this revenue showed year-on-year growth compared with the prior period, underlining the structural demand for e-health and practice management software solutions.

The same sources point to a year-on-year improvement in profitability metrics such as EBITDA and operating margin in the most recent reporting period, although specific margin levels vary by segment and product line; this improvement is part of the reason why the market has rewarded CompuGroup Medical stock with a positive performance so far in 2026.

Analyst views and risk considerations

Analyst commentary collected in recent days focuses mainly on the sustainability of CompuGroup Medical’s revenue growth and the potential impact of regulatory changes in European healthcare IT markets, rather than on short-term price movements.

Across coverage, a recurring theme is that CompuGroup Medical’s revenue mix between recurring software subscriptions and implementation projects gives a degree of visibility, but that contract timing and public-sector budget cycles can still lead to volatility in quarterly figures, which investors need to factor into their expectations.

Another risk discussed in analyst notes is the competitive pressure from other international health IT vendors, which could affect pricing in some segments; however, the company’s established customer base in hospitals, labs and physician practices is often cited as a counterbalancing strength.

CGM clinical software as a flagship offering

A key representative product within CompuGroup Medical’s portfolio is its CGM clinical and practice management software, which supports physicians and medical institutions in managing patient data, billing and workflow processes.

Recent product communication highlights that this software is increasingly integrated with telemedicine and electronic prescription modules, aligning CompuGroup Medical with broader trends in virtual care and interoperable health records across Europe.

CompuGroup stock price and investor perspective

CompuGroup Medical stock trades primarily on Xetra in euros; the current reference price of EUR 27.95 as of September 7, 2026, according to wallstreet-online, places the shares below their 52-week high but comfortably above the 52-week low, reflecting both prior gains and a degree of recent consolidation.

More news and analyses on CompuGroup Medical stock